Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Sanofi says European Commission approves Aubagio for children and adolescents » 09:50
06/18/21
06/18
09:50
06/18/21
09:50
SNY

Sanofi

$52.27 /

-0.95 (-1.79%)

The European Commission…

The European Commission has approved Aubagio for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis, or RRMS, Sanofi announced. "The approval confirms Aubagio as the first oral multiple sclerosis therapy for first-line treatment of children and adolescents with MS in the European Union," the company said.

ShowHide Related Items >><<
SNY Sanofi
$52.27 /

-0.95 (-1.79%)

SNY Sanofi
$52.27 /

-0.95 (-1.79%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
SNY Sanofi
$52.27 /

-0.95 (-1.79%)

SNY Sanofi
$52.27 /

-0.95 (-1.79%)

SNY Sanofi
$52.27 /

-0.95 (-1.79%)

Over a week ago
Hot Stocks
Sanofi says Phase 3 data from CADENZA study met primary composite endpoint » 07:07
06/11/21
06/11
07:07
06/11/21
07:07
SNY

Sanofi

$53.78 /

+0.95 (+1.80%)

Results from Part A of…

Results from Part A of CADENZA, a pivotal Phase 3 double-blind, placebo-controlled study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease, or CAD, without a recent history of blood transfusion within the prior six months, will be presented in an oral session at the European Hematology Association 2021 Congress, Sanofi announced. The data demonstrated treatment with sutimlimab resulted in rapid and sustained inhibition of C1-activated hemolysis in people with CAD, noted within one week of treatment, and clinically significant improvements in hemoglobin and fatigue when compared to placebo during the course of the study. The primary efficacy outcome was the proportion of patients who met all three of the following components: improvement in hemoglobin greater than or equal to 1.5 g/dL from baseline at treatment assessment timepoint, average of Weeks 23, 25, and 26; avoidance of transfusions from Week 5 through Week 26; and avoidance of other CAD-related therapies beyond what was permitted from Week 5 through Week 26. The secondary efficacy measures assessed improvement from baseline in key indicators of the disease process including hemoglobin, bilirubin, lactate dehydrogenase levels, and quality of life as measured by Functional Assessment of Chronic Illness Therapy-Fatigue Score.

ShowHide Related Items >><<
SNY Sanofi
$53.78 /

+0.95 (+1.80%)

SNY Sanofi
$53.78 /

+0.95 (+1.80%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
SNY Sanofi
$53.78 /

+0.95 (+1.80%)

SNY Sanofi
$53.78 /

+0.95 (+1.80%)

SNY Sanofi
$53.78 /

+0.95 (+1.80%)

Hot Stocks
Innate Pharma to present latest ANKET preclinical data » 05:30
06/10/21
06/10
05:30
06/10/21
05:30
IPHA

Innate Pharma

$3.85 /

+0.1 (+2.67%)

, SNY

Sanofi

$52.84 /

+0.79 (+1.52%)

Innate Pharma (IPHA)…

Innate Pharma (IPHA) announced it will present the latest preclinical data from its next- generation, proprietary, multi-specific NK cell engager platform known as ANKET at the Federation of Clinical Immunology Societies, or FOCIS, meeting. Specifically, Innate will share new data from its tetra-specific ANKET molecule, which is the first NK cell engager technology to engage activating receptors, or NKp46 and CD16, a tumor antigen and a cytokine in a single molecule. This latest innovation leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells. This data set is built on Innate's existing tri-specific NK cell engager technology, which has demonstrated NK cell activation, cytotoxicity and efficient control of tumor growth in preclinical models. In preclinical studies, tetra-specific ANKET demonstrated in vitro the ability to induce human NK cell proliferation, cytokine production and cytolytic activity against cancer cells expressing the targeted antigen. Tetra-specific ANKET also demonstrated in vivo anti-tumor efficacy in several tumor models, allowing regression of established tumors as well as control of metastasis, associated with increased NK cell infiltration, cytokine and chemokine production at the tumor site. ANKET showed also pharmacodynamic effect, low systemic cytokine release and a manageable safety profile in non-human primates. Innate's lead ANKET asset, IPH6101, has shown anti-tumor activity in pre-clinical models, including encouraging pharmacokinetic, pharmacodynamic and safety data in preliminary non-human primate studies. In January, Sanofi (SNY) made the decision to progress this program into investigational new drug, or IND-enabling studies. As part of the previously announced research collaboration, the companies are also currently working on the second research program.

ShowHide Related Items >><<
SNY Sanofi
$52.84 /

+0.79 (+1.52%)

IPHA Innate Pharma
$3.85 /

+0.1 (+2.67%)

IPHA Innate Pharma
$3.85 /

+0.1 (+2.67%)

12/15/20
Fly Intel: Top five analyst downgrades
12/15/20 SVB Leerink
Innate Pharma downgraded to Market Perform at SVB Leerink
12/15/20 SVB Leerink
Innate Pharma downgraded to Market Perform from Outperform at SVB Leerink
12/14/20 H.C. Wainwright
Innate Pharma price target lowered to $11.50 from $13 at H.C. Wainwright
SNY Sanofi
$52.84 /

+0.79 (+1.52%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
SNY Sanofi
$52.84 /

+0.79 (+1.52%)

SNY Sanofi
$52.84 /

+0.79 (+1.52%)

SNY Sanofi
$52.84 /

+0.79 (+1.52%)

Hot Stocks
Translate Bio achieves milestone related to influenza mRNA vaccine program » 07:52
06/07/21
06/07
07:52
06/07/21
07:52
TBIO

Translate Bio

$18.61 /

+0.19 (+1.03%)

, SNY

Sanofi

$52.43 /

+0.53 (+1.02%)

Translate Bio (TBIO)…

Translate Bio (TBIO) announced it has achieved a manufacturing milestone under the collaboration with Sanofi Pasteur related to its influenza mRNA vaccine program. Translate Bio will receive a $50 million payment from Sanofi Pasteur (SNY) for the successful manufacture, release, and delivery of clinical drug product to supply Sanofi Pasteur's Phase 1 influenza clinical trial which is anticipated to begin in the coming weeks. The Phase 1 clinical trial will evaluate a monovalent influenza vaccine candidate and will inform the next steps of the mRNA-based influenza vaccine program.

ShowHide Related Items >><<
TBIO Translate Bio
$18.61 /

+0.19 (+1.03%)

SNY Sanofi
$52.43 /

+0.53 (+1.02%)

TBIO Translate Bio
$18.61 /

+0.19 (+1.03%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
Translate Bio downgraded to Market Perform from Outperform at SVB Leerink
03/18/21 Roth Capital
Translate Bio price target lowered to $28 from $37 at Roth Capital
SNY Sanofi
$52.43 /

+0.53 (+1.02%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
TBIO Translate Bio
$18.61 /

+0.19 (+1.03%)

SNY Sanofi
$52.43 /

+0.53 (+1.02%)

  • 26
    Jun
SNY Sanofi
$52.43 /

+0.53 (+1.02%)

TBIO Translate Bio
$18.61 /

+0.19 (+1.03%)

SNY Sanofi
$52.43 /

+0.53 (+1.02%)

Hot Stocks
Sanofi partners with BIG, EORTC and AFT to initiate SERD trial » 05:40
06/04/21
06/04
05:40
06/04/21
05:40
SNY

Sanofi

$51.90 /

+0.03 (+0.06%)

Sanofi is partnering with…

Sanofi is partnering with the Breast International Group, or BIG, the European Organization for Research and Treatment of Cancer, or EORTC, and the Alliance Foundation Trials, or AFT, to initiate a pivotal trial of an oral selective estrogen receptor degrader, or SERD, in the adjuvant setting. The Phase 3 AMEERA-6 study will evaluate the efficacy and safety of Sanofi's amcenestrant vs tamoxifen for women with estrogen receptor-positive, or ER+, breast cancer who were unable to continue their adjuvant aromatase inhibitor, or AI, therapy. As per the terms of the pre-study agreement, Sanofi will be the sponsor and will provide funding and investigational drug product for the global study. BIG will conduct the study within the BIG network, EORTC will oversee study management and data analysis, as well as the medical management, and AFT will conduct the United States portion of the study. Sanofi will conduct this global study in selected countries outside the geographical scope of the academic networks, as further described in a follow-on agreement under negotiation among the four parties. The protocol is being developed in collaboration with all four parties, including AFT, BIG, EORTC and Sanofi.

ShowHide Related Items >><<
SNY Sanofi
$51.90 /

+0.03 (+0.06%)

SNY Sanofi
$51.90 /

+0.03 (+0.06%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
SNY Sanofi
$51.90 /

+0.03 (+0.06%)

SNY Sanofi
$51.90 /

+0.03 (+0.06%)

SNY Sanofi
$51.90 /

+0.03 (+0.06%)

Hot Stocks
Sanofi launches EUR3M Planet Mobilization fund » 08:10
06/03/21
06/03
08:10
06/03/21
08:10
SNY

Sanofi

$51.87 /

-0.6 (-1.14%)

As part of a…

As part of a long-standing commitment to reduce the environmental footprint of the company's products and activities, Sanofi launched a EUR 3 million Planet Mobilization fund to support employee ideas and projects that will further contribute to a healthier environment. This year, three Sanofi teams will have their projects funded. For several years, Sanofi has been implementing a global environmental roadmap, Planet Mobilization, which is embedded in Sanofi's long-term strategy. The program covers all Sanofi activities and sites and the entire lifecycle of products, from raw materials used in production all the way to their disposal.

ShowHide Related Items >><<
SNY Sanofi
$51.87 /

-0.6 (-1.14%)

SNY Sanofi
$51.87 /

-0.6 (-1.14%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
SNY Sanofi
$51.87 /

-0.6 (-1.14%)

SNY Sanofi
$51.87 /

-0.6 (-1.14%)

SNY Sanofi
$51.87 /

-0.6 (-1.14%)

Hot Stocks
Sanofi, Merck announce U.S. availabity of pediatric combination vaccine » 06:48
06/01/21
06/01
06:48
06/01/21
06:48
SNY

Sanofi

$53.46 /

+0.49 (+0.93%)

, MRK

Merck

$75.90 /

-0.01 (-0.01%)

Vaxelis developed as part…

Vaxelis developed as part of a partnership between Sanofi Pasteur (SNY) and Merck (MRK) is now available in the U.S. Vaxelis is a hexavalent (combination vaccine available in the U.S. Vaxelis is a vaccine given to protect your child from getting diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B. Vaxelis is given to children from 6 weeks through 4 years of age and is given as 3 shots, one at 2 months, one at 4 months and one at 6 months of age. On February 11, 2021, the U.S. Centers for Disease Control and Prevention's Advisory Committee included Vaxelis as a combination vaccine option in the CDC's recommended Child and Adolescent Immunization Schedule. Vaxelis will be widely available in the U.S. through traditional public and private channels, including directly from Sanofi Pasteur via vaccineshoppe.com.

ShowHide Related Items >><<
SNY Sanofi
$53.46 /

+0.49 (+0.93%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

SNY Sanofi
$53.46 /

+0.49 (+0.93%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
MRK Merck
$75.90 /

-0.01 (-0.01%)

05/20/21
Fly Intel: Top five analyst downgrades
05/20/21 Argus
Merck downgraded to Hold at Argus ahead of Organon spinoff
05/20/21 Argus
Merck downgraded to Hold from Buy at Argus
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
SNY Sanofi
$53.46 /

+0.49 (+0.93%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

SNY Sanofi
$53.46 /

+0.49 (+0.93%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

SNY Sanofi
$53.46 /

+0.49 (+0.93%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

Hot Stocks
Merck and Sanofi's Vaxelis pediatric vaccine is now available in the U.S. » 06:48
06/01/21
06/01
06:48
06/01/21
06:48
MRK

Merck

$75.90 /

-0.01 (-0.01%)

, SNY

Sanofi

$53.46 /

+0.49 (+0.93%)

Vaxelis, a Diphtheria and…

Vaxelis, a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine, developed as part of a partnership between Sanofi Pasteur, the global vaccines business unit of Sanofi (SNY), and Merck (MRK), known as MSD outside the U.S. and Canada, is now available in the U.S. Vaxelis is the first and only hexavalent combination vaccine available in the U.S. Vaxelis is a vaccine given to protect children from getting diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B.

ShowHide Related Items >><<
SNY Sanofi
$53.46 /

+0.49 (+0.93%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

05/20/21
Fly Intel: Top five analyst downgrades
05/20/21 Argus
Merck downgraded to Hold at Argus ahead of Organon spinoff
05/20/21 Argus
Merck downgraded to Hold from Buy at Argus
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
SNY Sanofi
$53.46 /

+0.49 (+0.93%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
SNY Sanofi
$53.46 /

+0.49 (+0.93%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

SNY Sanofi
$53.46 /

+0.49 (+0.93%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

SNY Sanofi
$53.46 /

+0.49 (+0.93%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

MRK Merck
$75.90 /

-0.01 (-0.01%)

Hot Stocks
Sanofi, GSK initiate Phase 3 clinical efficacy study of COVID vaccine candidate » 06:45
05/27/21
05/27
06:45
05/27/21
06:45
SNY

Sanofi

$53.89 /

+0.17 (+0.32%)

, GSK

GlaxoSmithKline

$38.70 /

+0.05 (+0.13%)

Sanofi (SNY) and…

Sanofi (SNY) and GlaxoSmithKline (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. The global randomized, double-blind, placebo-controlled Phase 3 study will include more than 35,000 volunteers aged 18 and older from several countries, including sites in the US, Asia, Africa and Latin America. The primary endpoint of the study is the prevention of symptomatic COVID-19 in SARS-CoV-2 naive adults, with secondary endpoints being the prevention of severe COVID-19 disease and prevention of asymptomatic infection. In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original D.614 virus, while a second stage will evaluate a second formulation targeting the B.1.351, or South African, variant. The design of the Phase 3 study, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate against a variety of circulating variants. "We are encouraged to see first vaccinations starting to take place in such an important, pivotal Phase 3 study, as we believe that our unique technology platform will provide a clinically-relevant vaccine option. We have adapted our vaccine development strategy based on forward-looking considerations as the virus continues to evolve, as well as anticipating what may be needed in a post-pandemic setting," said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur.

ShowHide Related Items >><<
SNY Sanofi
$53.89 /

+0.17 (+0.32%)

GSK GlaxoSmithKline
$38.70 /

+0.05 (+0.13%)

SNY Sanofi
$53.89 /

+0.17 (+0.32%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
GSK GlaxoSmithKline
$38.70 /

+0.05 (+0.13%)

05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
SNY Sanofi
$53.89 /

+0.17 (+0.32%)

GSK GlaxoSmithKline
$38.70 /

+0.05 (+0.13%)

SNY Sanofi
$53.89 /

+0.17 (+0.32%)

GSK GlaxoSmithKline
$38.70 /

+0.05 (+0.13%)

SNY Sanofi
$53.89 /

+0.17 (+0.32%)

GSK GlaxoSmithKline
$38.70 /

+0.05 (+0.13%)

GSK GlaxoSmithKline
$38.70 /

+0.05 (+0.13%)

Recommendations
Olema selloff brings 'compelling' entry point, says JPMorgan » 07:08
05/25/21
05/25
07:08
05/25/21
07:08
OLMA

Olema Oncology

$25.25 /

+0.45 (+1.81%)

, SNY

Sanofi

$53.67 /

-0.12 (-0.22%)

Olema Oncology (OLMA)…

Olema Oncology (OLMA) shares are down 48% year-to-date due to the broader biotech market volatility as well as competitive concerns in the complete estrogen receptor antagonist/selective ER degrader class following Sanofi's (SNY) AMEERA-3 study readout, JPMorgan analyst Anupam Rama tells investors in a research note. The analyst believes AMEERA-3 concerns are overblown and that the properties of OP-1250 are differentiated. Current share levels provide a "compelling entry point" for Olema shares heading into initial Phase 1 OP-1250 results in the second half of 2021, contends Rama.

ShowHide Related Items >><<
SNY Sanofi
$53.67 /

-0.12 (-0.22%)

OLMA Olema Oncology
$25.25 /

+0.45 (+1.81%)

OLMA Olema Oncology
$25.25 /

+0.45 (+1.81%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
SNY Sanofi
$53.67 /

-0.12 (-0.22%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SNY Sanofi
$53.67 /

-0.12 (-0.22%)

OLMA Olema Oncology
$25.25 /

+0.45 (+1.81%)

  • 19
    Nov
SNY Sanofi
$53.67 /

-0.12 (-0.22%)

SNY Sanofi
$53.67 /

-0.12 (-0.22%)

OLMA Olema Oncology
$25.25 /

+0.45 (+1.81%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.